Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. ...

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased aTyr Pharma common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

文章核心观点 - 律师事务所Robbins LLP提醒投资者，针对生物技术公司aTyr Pharma Inc (NASDAQ: ATYR) 在2025年1月16日至9月12日期间涉嫌误导投资者的集体诉讼已提起 [1] - 诉讼指控公司高管在隐瞒其候选药物Efzofitimod实际疗效的情况下，对外表达对三期临床试验设计的信心 [2] - 2025年9月15日，公司宣布EFZO-FIT三期研究未达到主要终点，导致股价单日暴跌83.2% [3] 诉讼相关指控 - 指控涉及aTyr公司针对肺结节病患者的Efzofitimod三期随机双盲安慰剂对照研究 (EFZO-FIT) [2] - 被告被指控在隐瞒该药物能否让患者完全停止使用类固醇的信息的同时，向投资者提供有关试验安全性和有效性的重要信息 [2] - 公司高管被指控对研究中采用的强制递减用药方法表示有信心 [2] 关键事件与市场影响 - 2025年9月15日，aTyr公司在投资者电话会中宣布EFZO-FIT研究未达到主要终点，即第48周时平均每日口服糖皮质激素剂量相较于基线的变化 [3] - 鉴于令人失望的顶线结果，公司宣布下一步将与FDA沟通以确定未来路径 [3] - 此消息导致公司普通股股价从2025年9月12日的收盘价每股6.03美元，暴跌至2025年9月15日的每股1.02美元，单日跌幅达83.2% [3] 公司背景 - aTyr Pharma Inc 是一家临床阶段生物技术公司，致力于利用进化智能将tRNA合成酶生物学转化为治疗纤维化和炎症的新疗法 [1]

Accessibility StatementSkip Navigation SAN FRANCISCO, Oct. 24, 2025 /PRNewswire/ -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. aTyr Pharma, Inc. (AYTR) Securities Litigation: The suits allege that aTyr and its top executives made false and misleading statements about the efficacy of its drug, Efzofitimod, leading investors to purchase sto ...

LOS ANGELES, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com. Mare ...

BENSALEM, Pa., Oct. 24, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ:Â ATYR). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ATYR PHARMA INC. (ATYR), CONTACT THE LAW OFFICES OF HOWARD G. SMITHÂ BEFORE DECEMBER 8, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of ...

Accessibility StatementSkip Navigation NEW YORK, Oct. 24, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of aTyr investors who were adversely affected by alleged securities fraud between January 16, 2025 and September 12, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/p ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming December 8, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired aTyr Pharma Inc. ("aTyr†or the "Company†) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the "Class Period†). IF YOU SUFFERED A LOSS ON YOUR ATYR INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO. ...

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional information] As detailed be ...

MIAMI, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The law firm of Shamis & Gentile, P.A. announces that it has filed a class action complaint for violations of the federal securities laws against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) and a senior executive of the Company. The case is pending in the U.S. District Court for the Southern District of California and is captioned King v. aTyr Pharma, Inc., No. 25-cv-02826 (the “King Action”). The King Action is related to the class action an investor ...